Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th1 responding C3H/HeN mice.

Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th1 responding C3H/HeN mice.

APMIS. 1997 Nov;105(11):838-42. Unique Identifier : AIDSLINE MED/98055272
Moser C; Johansen HK; Song Z; Hougen HP; Rygaard J; Hoiby N; Department of Clinical Microbiology, Rigshospitalet, Copenhagen,; Denmark.

Abstract: The chronic Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) is characterized by a pronounced antibody response and microcolonies surrounded by numerous polymorphonuclear neutrophils (PMN). Poor prognosis is correlated with a high antibody response to P. aeruginosa antigens. An animal model of this infection was established in two strains of mice: C3H/HeN and BALB/c, generally known as Th1 and Th2 responders, respectively, which were challenged with alginate-embedded P. aeruginosa. Mortality was significantly lower in C3H/HeN compared to BALB/c mice (p < 0.025). P. aeruginosa was cleared more efficiently in C3H/HeN mice and significantly more C3H/HeN mice showed normal lung histopathology (p < 0.02), and we found significantly fewer microabscesses in C3H/HeN mice than in BALB/c mice (p < 0.005). In supernatants from P. aeruginosa antigen and concanavalin A-stimulated spleen cells from the two strains of mice, the interferon-(IFN-) gamma levels were higher, whereas IL-4 levels were lower in C3H/HeN mice than in BALB/c mice. The implications of these findings for CF patients with chronic P. aeruginosa lung infection are discussed.

Keywords: Animal Chronic Disease Female Interferon Type II/METABOLISM Interleukin-4/METABOLISM Lymphocyte Transformation Mice Mice, Inbred BALB C/IMMUNOLOGY Mice, Inbred C3H/IMMUNOLOGY Pneumonia, Bacterial/*IMMUNOLOGY/MICROBIOLOGY Pseudomonas aeruginosa/*PATHOGENICITY Pseudomonas Infections/*IMMUNOLOGY Spleen/IMMUNOLOGY Support, Non-U.S. Gov't Th1 Cells/*IMMUNOLOGY Th2 Cells/*IMMUNOLOGY JOURNAL ARTICLE
980228
M9820738

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .